Counterfeit GLP-1s and Scams: How to Protect Yourself

High demand, high prices, and a narrowing supply of cheap compounded product have produced exactly the conditions fraud thrives in. Regulators on both sides of the border are now issuing explicit warnings, and the tactics have become more sophisticated than obvious spam.

What Regulators Are Warning About

The Better Business Bureau has issued a scam alert specifically for weight loss and GLP-1 products, describing scammers targeting consumers with fake texts, fraudulent online pharmacies, and bogus offers. Reporting on the alert notes the tactics now include fake celebrity endorsements, fraudulent websites, and AI-generated advertisements aimed at people searching for affordable GLP-1 medications.

Health Canada has published a recall and alert directed at people considering buying GLP-1 drugs such as Ozempic or Mounjaro, warning about fake and unauthorized versions and advising consumers not to buy or use unauthorized products containing semaglutide or tirzepatide.

The FDA has warned companies illegally selling unapproved drugs containing semaglutide, tirzepatide, retatrutide, survodutide or mazdutide — the last three being investigational compounds not approved anywhere in the world.

The Research Peptide Problem

This is the most dangerous corner of the market and the fastest growing, precisely because regulated compounding has narrowed. Sellers market vials as "research peptides," typically with a disclaimer that they are not for human consumption — a legal fiction that everyone involved understands.

Retatrutide is the most sought-after of these because of its trial results. It has not been approved anywhere in the world and is legally available only to participants in clinical trials. Anything sold as retatrutide outside a trial is, by definition, of unverified origin.

What is actually unknown when you inject one of these: identity (is it the compound claimed?), purity (what else is in it?), potency (is the dose what the label says?), and sterility (was it made under aseptic conditions?). A dosing error of tenfold is entirely possible when concentration is unverified, and injectable products carry infection risk that oral products do not.

How to Verify a Source

• A prescription is required. Any site selling GLP-1 medication without one is illegitimate, full stop.
• A licensed clinician evaluates you. A form with no clinical review is not a consultation.
• The pharmacy is identifiable. You should be able to learn which pharmacy or facility dispenses your medication.
• Payment is normal. Requests for wire transfer, cryptocurrency, gift cards, or peer-to-peer payment apps are a strong signal.
• The company is contactable. A real address, phone number, and named clinical leadership.
• The price is plausible. Legitimate floors now exist — Foundayo from around $149/month, manufacturer-direct channels, and a $50 Medicare GLP-1 Bridge rate. Prices far below every regulated option tell you about the product.

Fake Reviews and Manufactured Trust

The fraud is not only in the products. Enforcement has extended to how these offerings are marketed: the FTC brought an action against a telemedicine company over allegations of misleading pricing, fake reviews and deceptive practices, and has issued a notice on penalty offenses concerning weight loss advertising. The FDA has sent warning letters to telehealth companies over false and misleading claims.

Practical implications for reading reviews: be sceptical of uniformly glowing testimonials with no specifics, celebrity endorsements that the celebrity has not confirmed, and dramatic before-and-after claims. AI-generated advertising has made fabricated endorsement cheap and convincing, which is precisely why the BBB called it out.

Warning Signs in a Product You Have Received

• Packaging or labelling that differs from previous fills — misspellings, wrong fonts, missing lot numbers
• Solution that is discoloured, cloudy, or contains particles
• A pen or device that operates differently from what you are used to
• No pharmacy label, or a label with no identifiable dispensing pharmacy
• An unexpected change in side effects or in effect at the same dose

If something looks wrong, do not use it. Contact your prescriber and pharmacy, and report suspected counterfeits to the FDA.

The Bottom Line

The conditions that created this market — high demand, high prices, tightening compounded supply — have not gone away, and the tactics have become more sophisticated with AI-generated ads and fabricated endorsements.

The protective rule is simple and worth holding to even when the price is tempting: prescription from a licensed clinician, medication from an identifiable licensed pharmacy. The genuine low-cost routes that now exist — an approved oral GLP-1 near $149/month, manufacturer-direct pricing, the Medicare Bridge at $50 — mean there is far less reason than there was two years ago to take the risk.